ArticleCell reports2022
Targeting EP2 receptor with multifaceted mechanisms for high-risk neuroblastoma.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 16 citations in OpenAlex.
- MYC in Oncogenesis and Therapeutic Implications.MedComm · 2026Review
- Development of highly potent EP2 antagonists as novel anti-inflammatory neuroprotectants.Bioorganic & medicinal chemistry · 2026Article
- Simvastatin reprograms lipid metabolism in B16.F10 melanoma cells to favor an early resistant phenotype.Scientific reports · 2026Article
- The role of prostanoids in the retina and optic nerve in health and disease.Progress in retinal and eye research · 2026Review
- Engineering with EP2/EP4 knockout and IL-15 transpresentation renders stem cell-derived NK cells self-persistent and resistant to PGE2 inhibition.Frontiers in immunology · 2026Article
- Direct Targeting of CXCR2 Receptor Inhibits Neuroblastoma Growth: An In Vitro Assessment.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Inflammatory markers including NLR, AFR and SII as prognostic factors in neuroblastoma.Scientific reports · 2025Article
- Modulating inflammatory prostaglandin E2 signaling to mitigate neurobehavioral comorbidities associated with seizure disorders.Acta pharmaceutica Sinica. B · 2025Review
- Glycerophospholipid-driven lipid metabolic reprogramming as a common key mechanism in the progression of human primary hepatocellular carcinoma and cholangiocarcinoma.Lipids in health and disease · 2024Article
- Complementary roles of EP2 and EP4 receptors in malignant glioma.British journal of pharmacology · 2023Article
- Targeting EP2 Receptor for Drug Discovery: Strengths, Weaknesses, Opportunities, and Threats (SWOT) Analysis.Journal of medicinal chemistry · 2023Review
- The inducible prostaglandin E synthase (mPGES-1) in neuroinflammatory disorders.Experimental biology and medicine (Maywood, N.J.) · 2023Review
- Neuroinflammatory mediators in acquired epilepsy: an update.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023Review
- Transient inhibition of microsomal prostaglandin E synthase-1 after status epilepticus blunts brain inflammation and is neuroprotective.Molecular brain · 2023Article
- Prostaglandin E2 in neuroblastoma: Targeting synthesis or signaling?Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Ablation of Siglec-E augments brain inflammation and ischemic injury.Journal of neuroinflammation · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Ruida HouDepartment of Pharmaceutical Sciences, Drug Discovery Center, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Ying YuDepartment of Pharmaceutical Sciences, Drug Discovery Center, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Madison N SluterDepartment of Pharmaceutical Sciences, Drug Discovery Center, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Lexiao LiDepartment of Pharmaceutical Sciences, Drug Discovery Center, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Jiukuan HaoDepartment of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX 77204, USA.
Jie FangDepartment of Surgery, Comprehensive Cancer Center, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Jun YangDepartment of Surgery, Comprehensive Cancer Center, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Graduate School of Biomedical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Department of Pathology and Laboratory Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Jianxiong JiangDepartment of Pharmaceutical Sciences, Drug Discovery Center, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, USA; Department of Anatomy and Neurobiology, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA; Neuroscience Institute, University of Tennessee Health Science Center, Memphis, TN 38163, USA. Electronic address: jjiang18@uthsc.edu.
University of Tennessee Health Science Center · USSt. Jude Children's Research Hospital · USUniversity of Houston · US
Funding
Inflammatory regulation of neurotrophin signaling in epileptogenesisR01NS100947 · NINDS · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI Jianxiong Jiang · 2018 to 2026
$2.8MDevelopment of small molecules to target KDM4BR01CA229739 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHEN, TAOSHENG, DAVIDOFF, ANDREW M · 2018 to 2021
$1.6MTargeting TRPC3 Channels for Epileptic SeizuresR61NS124923 · NINDS · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI JIANG, JIANXIONG, LI, WEI · 2022 to 2023
$765kTargeting Prostaglandin Receptor EP2 for Glioma and Associated EpilepsyR21NS109687 · NINDS · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI JIANG, JIANXIONG · 2019 to 2020
$418kThe role of JMJD6 in MYC-mediated neuroblastomaR03CA212802 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI YANG, JUN · 2017 to 2018
$180kNCI NIH HHS R01 CA229739NCI NIH HHS R03 CA212802NINDS NIH HHS R01 NS100947NINDS NIH HHS R21 NS109687NINDS NIH HHS R61 NS124923
Abstract
Prostaglandin E
Indexed as
NeuroblastomaReceptors, Prostaglandin E, EP2 SubtypeAnimalsDinoprostoneHumansMiceMice, KnockoutMice, NudeTumor MicroenvironmentDinoprostoneReceptors, Prostaglandin E, EP2 Subtype11q deletionangiogenesisantagonistchildhood cancerCOXCP: CancerEP2inflammationMYCN amplificationPGE(2)tumor microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.